1. Scrip
  2. >>Business
  3. >>Earnings

Gilead’s TIGIT Program Perks Up After Lung Cancer Letdown

Oncology, HIV Offer R&D Catalysts In 2024

 
• By Alaric DeArment

The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.

• Source: Shutterstock

Gilead Sciences, Inc. got what it called encouraging news from its anti-PD-1/TIGIT program just before announcing its third quarter earnings as a Phase II study showed clinical activity for the immuno-oncology combination in upper gastrointestinal cancers. It also highlighted a number of oncology, inflammation and virology catalysts for 2024, including earlier-than-expected data for its long-acting HIV pre-exposure prophylaxis (PrEP) program.

Foster City, CA-based Gilead announced its third quarter earnings on 7 November, with overall revenues of $7.1bn that were flat compared with $7bn in the third quarter of 2022, but...

Key Takeaways

  • Gilead announced early data from a Phase II study of zimberelimab/domvanalimab in upper GI cancers the same day it announced Q3 earnings.

  • The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

More from Business

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.